David Sachs Biography and Net Worth

CFO of ImmunityBio

Currently, David Sachs holds the position of Chief Financial Officer at ImmunityBio, Inc. He is also on the board of Keyssa, Inc., Mox Networks LLC, PacketFabric, Inc. and Chan Soon-Shiong Institute For Medicine.

He previously occupied the position of Principal at Nant Capital LLC, Chief Financial Officer of Integrity Healthcare LLC and Chief Financial Officer of NantKwest, Inc.

He received an undergraduate degree from the University of California, Los Angeles and an MBA from Anderson School of Management.

How old is David C. Sachs?: Mr. Sachs is currently 46 years old. There are 6 older executives and no younger executives at ImmunityBio. The oldest executive at ImmunityBio is Dr. Hans Georg Klingemann M.D., Ph.D., Chief Science Officer of Cellular, who is 74 years old. Learn More on David C. Sachs' age.
How do I contact David C. Sachs?: The corporate mailing address for Mr. Sachs and other ImmunityBio executives is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. ImmunityBio can also be reached via phone at (858) 633-0300 and via email at [email protected]. Learn More on David C. Sachs' contact information.
Has David C. Sachs been buying or selling shares of ImmunityBio?: David C. Sachs has not been actively trading shares of ImmunityBio during the last ninety days. Learn More on David C. Sachs' trading history.
Who are ImmunityBio's active insiders?: ImmunityBio's insider roster includes Richard Adcock (CEO), Michael Blaszyk (Director), Cheryl Cohen (Director), David Sachs (CFO), and Barry Simon (Director). Learn More on ImmunityBio's active insiders.
Are insiders buying or selling shares of ImmunityBio?: In the last year, ImmunityBio insiders bought shares 2 times. They purchased a total of 96,915 shares worth more than $268,516.25. The most recent insider tranaction occured on June, 5th when Director Michael D Blaszyk bought 71,915 shares worth more than $197,766.25. Insiders at ImmunityBio own 83.4% of the company. Learn More about insider trades at ImmunityBio.
Information on this page was last updated on 6/5/2023.

David C. Sachs Insider Trading History at ImmunityBio

David C. Sachs Buying and Selling Activity at ImmunityBio

ImmunityBio Company Overview

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies. Its lead biologic commercial product candidate is Anktiva, an IL-15 superagonist antibody-cytokine fusion protein for the treatment of bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease. The company also develops other therapeutic agents for the treatment of liquid and solid tumors, including bladder, lung, colorectal, and ovarian cancers, as well as glioblastoma multiforme, acute myeloid leukemia, and human immunodeficiency virus. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., and Viracta Therapeutics, Inc. The company is based in San Diego, California.

Today's Range

Now: $5.49

$4.84

$6.19

50 Day Range

MA: $5.19

$3.50

$6.17

2 Week Range

Now: $5.49

$1.25

$6.93

Volume

30,653,127 shs

Average Volume

4,385,710 shs

Market Capitalization

$3.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23

The Best AI Stock to Own in the World Today is Trading for Just $25

From Banyan Hill Publishing | Ad

See how you can invest alongside him